Associated Papers
A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant.
Auen T et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2026
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.
Zając AE et al.
International Journal of Molecular Sciences, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
Jones RL et al.
Nature Communications, 2026
Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies.
Gilson P et al.
International Journal of Molecular Sciences, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1.
Bajaj M et al.
Rsc Advances, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Chien KS et al.
Clinical Lymphoma, Myeloma & Leukemia, 2025
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
Harding JJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
Next-Generation Sequencing Reveals a Diagnostic and Prognostic Role of the TP53 R273C Mutation in Lower-Grade, IDH-Mutant Astrocytomas.
Navarro L et al.
International Journal of Molecular Sciences, 2025
High depth targeted next-generation sequencing in vascular malformations.
Pakhathirathien P et al.
Human Molecular Genetics, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.
Boertjes EL et al.
Blood Advances, 2025
Coexistence of IDH1 Mutation and KIAA1549::BRAF Fusion in a Diffuse Glioma: A Case Report With Clinical, Radiological, and Pathological Correlation.
Das S et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2025
Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia.
Sommer C et al.
Scientific Reports, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders.
Esai Selvan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Clinicopathological and Molecular Profiling of Adult-Type Diffuse Glioma Using Immunohistochemistry and Real-Time Polymerase Chain Reaction: Study from a Tertiary Care Cancer Center in Western India.
Kaur K et al.
Neurology India, 2025
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Incident Abdominal Aortic Aneurysm.
Tan Y et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
Morfouace M et al.
European Journal of Cancer (oxford, England : 1990), 2025
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis.
Dang D et al.
Cancer Cell, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line.
Saisuwan K et al.
Human Cell, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Tumor diagnosis recharacterization enabled by comprehensive genomic profiling to guide precision medicine strategy.
Carr A et al.
Npj Precision Oncology, 2025
Real-World Genomic Landscape of Gastrointestinal Cancers in Asia and the Middle East Using Comprehensive Circulating Tumor DNA Next-Generation Sequencing.
Muto M et al.
Oncology Research and Treatment, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.
Schwartz AV et al.
The Journal of Biological Chemistry, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.
Ragaini S et al.
Blood Advances, 2025
Reviewing the IDH1 Mutation-Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies.
Wang Y et al.
Chemical Biology & Drug Design, 2025
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.
Colin-Leitzinger C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.
Wen S et al.
Nature Genetics, 2025
Isocitrate dehydrogenase 1 gene mutations: a case review unveiling its biological impact on disease progression, prognosis and treatment in Chilean patients.
de Mayo Glasser T et al.
Bjr Case Reports, 2025
Evaluation of an IDH1/2 Mutation FastTrack Assay for Patients with Cholangiocarcinoma.
Winter M et al.
Cancers, 2025
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.
Gui G et al.
Bone Marrow Transplantation, 2025
The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia.
Di J et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.
DiPeri TP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.
Pagani F et al.
Acta Neuropathologica, 2025
Clonal Hematopoiesis Associates with Prevalent and Incident Cardiometabolic Disease in High-Risk Individuals.
Regan JA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration.
Suzuki S et al.
Plos One, 2025
A Novel Germline MUTYH Mutation (p.W156∗) in High-Grade Astrocytoma, IDH Mutant.
Zhang L et al.
Human Mutation, 2025